Cellectis Announces Upcoming Presentations At The 56th Annual Meeting Of American Society of Hematology

PARIS--(BUSINESS WIRE)--Regulatory News : Cellectis SA (Paris:ALCLS) (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART-cells (UCART), today announced that three abstracts on the Company’s CART-cell development programs were accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco, December 6-9, 2014.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC